Ono Pharmaceutical has filed a patent for a prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis. The agent contains a compound with LPA3 agonistic activity or a salt thereof. The patent claims that the agent can be used as a treatment for idiopathic interstitial pneumonia. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ono Pharmaceutical, Peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia
A recently filed patent (Publication Number: US20230310376A1) describes a prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia. The agent comprises a compound with LPA3 agonistic activity or a salt thereof. Idiopathic interstitial pneumonia, specifically idiopathic pulmonary fibrosis, can be prevented and/or treated using this agent. The compound suppresses fibrosis, a key characteristic of idiopathic interstitial pneumonia.
The patent also outlines a method for preventing and/or treating idiopathic interstitial pneumonia in a subject in need. The method involves administering an effective amount of the compound with LPA3 agonistic activity or a salt thereof to the subject. This administration of the compound can suppress pulmonary fibrosis in the subject. The method is applicable to mammals, including humans. The specific compound mentioned in the patent is 3-[(cyclobutylamino)methyl]-1-(4-methylbenzyl)-1H-indol-2-carboxylic acid or a salt thereof.
Idiopathic interstitial pneumonia, particularly idiopathic pulmonary fibrosis, is a serious and often fatal lung disease characterized by progressive scarring of the lung tissue. Currently, there are limited treatment options available for this condition. The filed patent proposes a novel prophylactic and/or therapeutic agent that targets the LPA3 receptor, which is involved in fibrosis. By activating this receptor, the compound aims to suppress fibrosis and potentially prevent or treat idiopathic interstitial pneumonia.
The method outlined in the patent provides a potential treatment approach for idiopathic interstitial pneumonia. Administering the compound with LPA3 agonistic activity or a salt thereof to a subject in need may help prevent or reduce the progression of pulmonary fibrosis, thereby improving the prognosis for individuals with idiopathic interstitial pneumonia. Further research and clinical trials will be necessary to validate the efficacy and safety of this compound as a therapeutic option for idiopathic interstitial pneumonia. However, the filed patent represents a promising development in the field and highlights the potential of targeting the LPA3 receptor for the treatment of this debilitating lung disease.
To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
